Eurofins Scientific

Eurofins Scientific is an international life sciences company operating in food & pharmaceutical products testings. Co. provides analytical testing services to clients from various industries including pharmaceutical, food, and environmental sectors. Co. offers analytical methods for evaluating the authenticity, origin, safety, identity, composition, and purity of biological substances & products. Co. verifies authenticity of products analyzed to detect dangerous components (pathogens, prions, pesticides, asbestos, mycotoxins, dioxins, toxic substances, etc.). Co. operates in Benelux, France, Germany, North America, Scandinavia, British Isles (U.K. & Republic of Ireland), & other countries.
  • TickerERF
  • ISINFR0000038259
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Moody's corrects treatment for Eurofins' hybrids, ratings are unchanged

Announcement: Moody's corrects treatment for Eurofins' hybrids, ratings are unchanged. Global Credit Research- 08 Sep 2020. Frankfurt am Main, September 08, 2020-- Moody's Investors Service corrects the basket classification and equity credit percentages of two out of three outstanding hybrid instruments.

Bruno de La Rochebrochard

EUROFINS SCIENTIFIC: A win/win position whatever the scenario | BUY | EUR575(-21%)

EUROFINS SCIENTIFIC - BUY | EUR575 A win/win position whatever the scenario Eurofins is not a diagnostic company… An extensive offer allowing to propose solutions to help fight Covid-19 A crisis that appears to be an opportunity A win/win position whatever the scenario

Dave Nicoski ...
  • Ross LaDuke

Int'l Insights: Bullish Developed Markets Stocks

Overweight Global Technology & Industrials The absence of breakdowns in both the US dollar (DXY) and the MSCI EAFE vs. EM ratio along with the positive correlation between the two allows us to continue sticking with EAFE over EM... see charts below. As long as the DXY's uptrend remains intact, we expect EAFE to continue outperforming EM. Below we highlight attractive and actionable themes within developed int'l markets: • Technology and Industrial Manufacturing. Technology and Industrials continue to be two of the most attractive Sectors globally -- overweight. These two Sectors account ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care Hitting On All Cylinders Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout... see chart below. • Market Ignoring Negative Headlines. Global equity markets continue to generally shrug off seemingly bearish headlines surrounding trade, Trump impeachment hearings, and ongoing protests in Hong Kong. This tells us that the good outweighs the bad in the eyes of the market. While we view the fact that none of these issues have yet to derail global...

Jérôme VINERIER

Analyse court terme - EUROFINS SCIENTIFIC : La reprise est une consolidation.

La tendance est baissière. La reprise est une consolidation. Les Stochastiques sont en zone de surachat. La baisse peut bientôt reprendre vers 399,00 €. La tendance de fond serait remise en cause en cas de franchissement de 492,30 €.

Jérôme VINERIER

Short term view - EUROFINS SCIENTIFIC : The recovery is a consolidation.

The trend is bearish. The recovery is a consolidation. Stochastics are at the overbought level. The fall can soon resume toward €399.00. The background trend would be questioned should prices rise above €492.30.

Jérôme VINERIER

Short term view - EUROFINS SCIENTIFIC : The trend is bearish.

The trend is bearish. The recovery is a consolidation. The fall might resume toward €399.00. The background trend would be questioned should prices rise above €492.30.

Bruno de La Rochebrochard

EUROFINS SCIENTIFIC: A win/win position whatever the scenario | BUY | EUR575(-21%)

EUROFINS SCIENTIFIC - BUY | EUR575 A win/win position whatever the scenario Eurofins is not a diagnostic company… An extensive offer allowing to propose solutions to help fight Covid-19 A crisis that appears to be an opportunity A win/win position whatever the scenario

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : No breaking news but management confident about 2020. The share price soared yesterday, here are the implications we expect. Neutral vs Buy

>Management confident about 2020 - Gilles Martin (CEO) discussed the group’s H1 performance during the conference call held yesterday at 3pm, but above all he set out its prospects for the rest of the year; the outlook seems rather bleak with respect to Covid-19, which is making a comeback or continuing to spread in various countries, and therefore favourable for Eurofins as the company generates sales from the virus theme with its related tests and services....

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : Pas de breaking news, mais un ton confiant pour 2020. Le cours a explosé à la hausse hier, les implications que nous voyons. Neutre vs Achat

>Un ton confiant pour 2020 - A l’occasion du call tenu hier à 15h, Gilles Martin (CEO) est revenu sur la performance du S1, mais a surtout donné sa vision du reste de l’année, que nous comprenons comme plutôt pessimiste sur le développement du COVID-19 avec des résurgences ou poursuite de propagation dans différents pays, et donc de facto plutôt positive pour Eurofins dans la mesure où la société réalise du CA sur cette thématique avec des tests ou services liés....

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : H1 2020 slightly above our expectations, COVID-19 tests have increased in July. Target price € 640 vs € 600

>Slightly higher than our forecasts - Eurofins this morning reported solid 2020 interim earnings, slightly ahead of our expectations. Sales totalled € 2,323m, up +7.2% of which 5.1% organic, up sequentially (org. Q2 6.1% vs 4.1% in Q1).Adjusted EBITDA stood at € 493m vs € 480me, i.e. an increase of +210bp (18.9%). SDIs (Separately Disclosed Items) came out at € 35m vs € 44m in n-1 (and an expected lower level in H2, the guidance being € 60m). The share of sales i...

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : S1 2020 légèrement au-dessus de nos attentes, les tests COVID-19 commencent à bien progresser en juillet. OC 640 € vs 600 €

>Légèrement au-dessus de nos attentes - Eurofins a publié ce matin ses résultats semestriels 2020, de bonne facture et un peu au-dessus de nos attentes. Le CA ressort à 2 323 M€, en progression de +7.2%, dont 5.1% en organique, et en accélération séquentielle (orga. T2 6.1% vs 4.1% au T1).L’EBITDA ajusté ressort à 493 M€ vs 480 M€e, soit une hausse de +210 pb (18.9%). Les SDI (Separately Disclosed Items) ressortent à 35 M€ vs 44 M€ en n-1 (et un niveau attendu en...

Moody's corrects treatment for Eurofins' hybrids, ratings are unchanged

Announcement: Moody's corrects treatment for Eurofins' hybrids, ratings are unchanged. Global Credit Research- 08 Sep 2020. Frankfurt am Main, September 08, 2020-- Moody's Investors Service corrects the basket classification and equity credit percentages of two out of three outstanding hybrid instruments.

Moody's assigns Baa3 to Eurofins' senior unsecured bonds and Ba2 to Eurofins' hybrid instruments

Rating Action: Moody's assigns Baa3 to Eurofins' senior unsecured bonds and Ba2 to Eurofins' hybrid instruments. Global Credit Research- 06 Aug 2020. Frankfurt am Main, August 06, 2020-- Moody's Investors Service, has today assigned a Baa3 rating to the existing senior unsecured bond instruments and a Ba2 rating to the existing subordinated hybrid bond instruments, all issued by Eurofins Scientific SE.

Maxime Kogge

Eurofins : Dans quelles émissions investir après le récent rallye ?

L'attribution par Moody's d'une notation 'Baa3' à Eurofins a enthousiasmé les marchés et fait bondir plusieurs des obligations de 5pts, une progression rarement vue dans un tel cas de figure. Nous revenons ici sur les motifs de cette annonce qui survient plus tôt que ce que tout le monde attendait. Nous examinons aussi les impacts pour Eurofins et les investisseurs. Après le rallye des derniers jours, nous tentons aussi d'identifier les émissions qui recèlent encore de l'upside. - ...

Maxime Kogge

Eurofins : Still some upside after the recent bond rally?

Moody's assigned on 24 July a first-time rating of 'Baa3' to Eurofins, which triggered a surge in bond prices with some of the issues up by 5 pts, an increase rarely seen in such a situation. Here we return to the reasons for the rating announcement, which came earlier than anyone expected. We also look at the impacts on Eurofins and investors. After the rally of the last few days, we are also trying to identify which issues still have upside. - >Moody's methodology is mor...

Eurofins Scientific SE (Eurofins): New Issuer

Our credit view of Eurofins, reflecting its leading position in bioanalytical testing sector and long-term growth prospects.l

Alain William

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 08/06/2020

...

Alain William

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 06/08/2020

...

Benoit Valleaux ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Geoffroy Michalet
  • Louis Boujard, CFA
  • Martial Descoutures
  • Philippe Ourpatian
  • Roland Pfaender,MBA,CFA,CCRA
  • Sebastien Malafosse
  • Stephane Houri
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/08/2020

Since 2009, the outperformance of growth has been due to investors' determination to protect themselves against sluggish growth and falling interest rates. If we adopt a sequential point of view, these two parameters evolve in favour of value: 1/ by base effect, apparent growth is expected to be strong on the face of it; 2/ the rapid growth of debt and ultimately the inflationary effects of the relocation of value chains may push long rates up. We propose a list of 18 stocks with a Bu...

EUROFINS SCIENTIFIC AG with less fundamental stars is reduced to Neutral

EUROFINS SCIENTIFIC AG (FR), a company active in the Health Care Providers industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date January 31, 2020, the closing price was EUR 486.00 and its expected value was estimat...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

Jehanne Leroy

Eurofins Scientific - Assemblée Générale des actionnaires du 26 Juin 2020

RémunérationsIl est proposé, pour la première fois de donner un avis consultatif sur le rapport et la politique de rémunération. Si la communication de la société concernant les rémunérations long-terme est parfaite, concernant le bonus, elle l’est nettement moins. Elle n’est même pas aux standards français ou européens puisque non seulement la société ne communique pas les bonus annuels effectivement attribués au titre de 2019, mais en plus, elle ne communique pas les critères de performance des bonus annuels. Ce manque de transparence n’est pas acceptable pour une société du SBF 120.

Expert Corporate Governance Service (ECGS)

Eurofins Scientific – AGM 30 June 2020

ITEMS 9 and 10: It is proposed, for the first time, to give an advisory opinion on the remuneration report and policy. While the Company's disclosure on long-term remuneration is perfect, its disclosure on bonuses is far less so. It is not even up to French or European standards, since not only does the Company not disclose the annual bonuses actually awarded for 2019, but it also does not disclose the performance criteria for the annual bonuses. This lack of transparency is not acceptable for a SBF 120 Company.  ITEM 1 of the EGM: It is proposed to renew the authorization to increase the capi...

Eurofins - Assemblée générale des actionnaires du 25 avril 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Eurofins Scientific – Proxinvest Corporate Governance Rating ® : D

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Proxy Report - 26/04/2018

Each year the company publishes the amount of the remuneration due to the executive directors but does not publish any information on the remuneration policy. In addition, the company does not submit any resolution that allows shareholders to approve. Therefore, we will recommend opposition of resolution 7 on the discharge for directors, even if this is a mandatory resolution in Luxembourg. The company proposes two resolution on the renewal of directors. We will support Patrizia Luchetta and Fereshteh Pouchantchi as Directors - both of them are free from conflicts of interest (resolutions 9 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch